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Background: Treatment of latent tuberculosis infection (LTBI) is a key component in U.S. tuberculosis control,
assisted by recent improvements in LTBI diagnostics and therapeutic regimens. Effectiveness of LTBI therapy,
however, is limited by patients’ willingness to both initiate and complete treatment. We aimed to evaluate the
demographic, medical, behavioral, attitude-based, and geographic factors associated with LTBI treatment initiation
and completion of persons presenting with LTBI to a public health tuberculosis clinic.
Methods: Data for this prospective cohort study were collected from structured patient interviews, self-administered
questionnaires, clinic intake forms, and U.S. census data. All adults (>17 years) who met CDC guidelines for LTBI
treatment between January 11, 2008 and May 6, 2009 at Wake County Health and Human Services Tuberculosis Clinic
in Raleigh, North Carolina were included in the study. In addition to traditional social and behavioral factors, a
three-level medical risk variable (low, moderate, high), based on risk factors for both progression to and transmission of
active tuberculosis, was included for analysis. Clinic distance and neighborhood poverty level, based on percent
residents living below poverty level in a person’s zip code, were also analyzed. Variables with a significance level <0.10
by univariate analysis were included in log binomial models with backward elimination. Models were used to estimate
risk ratios for two primary outcomes: (1) LTBI therapy initiation (picking up one month’s medication) and (2) therapy
completion (picking up nine months INH therapy or four months rifampin monthly).
Results: 496 persons completed medical interviews and questionnaires addressing social factors and attitudes toward
LTBI treatment. 26% persons initiated LTBI therapy and 53% of those initiating completed therapy. Treatment initiation
predictors included: a non-employment reason for screening (RR 1.6, 95% CI 1.0-2.5), close contact to an infectious TB
case (RR 2.5, 95% CI 1.8-3.6), regular primary care(RR 1.4, 95% CI 1.0-2.0), and history of incarceration (RR 1.7, 95%
CI 1.0-2.8). Persons in the “high” risk category for progression/transmission of TB disease had higher likelihood of
treatment initiation (p< 0.01), but not completion, than those with lower risk.
Conclusions: Investment in social support and access to regular primary care may lead to increased LTBI therapy
adherence in high-risk populations.
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Latent tuberculosis infection (LTBI) treatment is a key
strategy to reduce TB disease incidence in industrialized
countries. Despite recent advances in LTBI diagnostics
and up to 90 percent efficacy of first-line therapy for
LTBI if taken properly, the proportion of patients who
complete prescribed therapy remains low, ranging from
50-65% [1-3]. Firstly, LTBI therapy initiation requires pa-
tient motivation and understanding of the diagnosis, ad-
equate communication between health department staff
and the patient, and availability of transportation to pick
up initial medications; barriers can arise to any of these
components. Therapy completion is a second, independ-
ent step with potentially different and additional barriers
at each visit, such as increased fear of medication side
effects, logistical issues, or negative attitudes towards
treatment that emerge over time.
Suboptimal compliance with traditional TB preventative
therapy has been attributed to various factors, including
duration of therapy, concerns about drug toxicity, and pill
burden [4]. Studies comparing four months of rifampin or
two months of rifampin and pyrazinamide to the trad-
itional nine months of isoniazid (INH) note improved ad-
herence to the shorter regimens [5-7], but increased
hepatotoxicity with rifampin-pyrazinamide led to with-
drawal of the regimen from CDC recommendations [8].
Studies evaluating three months of rifampin plus INH ver-
sus six months of INH, have noted no significant difference
in completion rates, possibly secondary to the increased
pill burden of a two-drug regimen [9]. A study of three
months directly-observed therapy with rifapentine and
INH versus self-administered nine months INH was also
recently completed, with adherence data forthcoming [10].
Aside from factors relating to therapy, other predictors
of medication adherence have been less prospectively
studied. Factors that have been consistently associated
with treatment completion in retrospective studies in-
clude non-U.S. birthplace [11-13] and recent exposure
to an active tuberculosis case [4,14]. Age and other
demographics have been less consistently associated with
treatment adherence across studies, with some suggest-
ing older age and others suggesting younger age correl-
ating with therapy adherence [11,13-16]. Certain patient
attitudes and social factors have also been correlated
with LTBI therapy non-completion, including perception
of a low risk of progression to active TB without LTBI
treatment, dislike of venipuncture [16], fear about side
effects [11,15], lower educational level [4,17], and un-
stable housing [4,11].
As identifying LTBI, initiating therapy, and adherence
to LTBI therapy serve as the cornerstones of U.S. TB
control efforts, prospective studies evaluating predictive
factors in treatment completion will not only help
modernize and improve treatment strategies, but alsoallow more educated and tailored interventions in cases
of noncompliance. The aim of this study was to under-
stand barriers to LTBI treatment initiation and comple-
tion by determining demographic, medical, behavioral,
attitude-based, and geographic factors potentially asso-
ciated with therapy adherence in LTBI-infected patients
recommended for treatment by the Wake County TB
clinic in Raleigh, North Carolina. Based on anecdotal ex-
perience in the clinic, we hypothesized that those per-
sons at highest risk of progressing to active TB disease
and spreading TB infection to others, as well as those
living in poorer geographical areas, would be less likely
to initiate and complete therapy.
Methods
Study setting and patient recruitment
All adults (>17 years) who met CDC guidelines for LTBI
treatment between January 11, 2008 and May 6, 2009 at
Wake County Tuberculosis Clinic in Raleigh, North Car-
olina were included in the study. Written informed con-
sent was waived by the Duke Institutional Review Board,
as this was considered an evaluation of a public benefit
program, and thus eligible for such a waiver under the
United States Code of Federal Regulations part 45
46.116(c)(1). The study was also approved by the Wake
County Human Rights-Consumer Affairs and Human
Research Committee.
Data collection
On entry to the TB clinic, a routine medical interview
was conducted, followed by a self-administered multiple
choice questionnaire addressing social factors and atti-
tudes toward LTBI treatment (Table 1). The question-
naire was developed based on the results of a focus
group study assessing TB-related knowledge, attitudes,
and behaviors among key populations in the region [18].
The questionnaire was validated by administering it to a
pilot population of individuals taking isoniazid therapy
at baseline and one month later; in this group test-retest
response concordance was >0.75.
Provision of treatment
All LTBI medications were provided free of charge by
the health department from an on-site pharmacy, which
recorded all medication pickups in a computerized system.
Statistical methods
Primary endpoints were 1) LTBI therapy initiation,
defined as picking up at least one month of medication,
and 2) therapy completion, defined as picking up nine
months of INH therapy within a 12-month period or
four months of rifampin within a six-month period. Uni-
variate analysis was performed with survey responses,
demographics, and medical risk data, using chi square
Table 1 Latent TB infection therapy initiation and completion based on responses to survey questions
Variable Treatment Initiation (%) P-value Treatment Completion (%) P-value*
Length of time at current residence
Less than 1 yr 20 0.01 52 0.8
Greater or equal to 1 year 31 55
Planned future time at current residence
Less than 1 yr 19 0.04 46 0.3
Greater or equal to 1 year 28 58
Education Level
No school 50 0.01 0 0.5
Elementary school 41 61
High school/GED 30 49
College 18 64
Graduate school 23 53
Cohabitance with any family members
Yes 27 0.6 57 0.3
No 24 47
Previous daily pill for at least 6 months
Yes 29 0.2 49 0.3
No 24 59
Regular primary care
Yes 37 <0.01 52 0.5
No 19 59
Easy access to health department
Yes 28 0.1 54 0.8
No 19 57
Plan to tell family/friends about positive skin test
Yes 25 59
No 35 0.1 30 0.02
Belief in getting sick from TB without medicine
Yes 34 <0.01 53 0.6
No 15 58
Fear of adverse effects from medicine
Yes 24 0.3 55 0.8
No 28 52
Belief in medicine efficacy
Yes 28 0.3 55 0.6
No 21 46
Belief in cure for TB
Yes 26 0.9 55 0.7
No 27 60
Fear of phlebotomy
Yes 25 0.8 50 0.7
No 26 56
*P-values represent differences in initiation/completion among responses (missing responses not included).
Goswami et al. BMC Public Health 2012, 12:468 Page 3 of 8
http://www.biomedcentral.com/1471-2458/12/468
Goswami et al. BMC Public Health 2012, 12:468 Page 4 of 8
http://www.biomedcentral.com/1471-2458/12/468test or Fischer’s exact test for categorical variables as ap-
propriate. For multi-level categorical variables, pairwise
testing was performed with chi square Univariate ana-
lysis was also performed to examine the relationship be-
tween the risk that an individual would transmit TB in
the future and the likelihood of a) initiating and b) com-
pleting LTBI treatment. Subjects were placed in three
risk categories, which were based on a combination of
medical risk (risk of progression to active TB) and social
risk (transmission risk due to suboptimal healthcare
utilization). Subjects with history of transplant, HIV, sili-
cosis, intravenous drug use, close contact to an infec-
tious TB case, or with evidence of old tuberculosis on
chest radiograph were placed in the “High risk” category.
Persons with diabetes, end-stage renal disease, history of
gastrectomy, homelessness, or being underweight were
placed in the “Moderate risk” category, and all others
were considered “Low risk.” Backward elimination was
used to arrive at a final log binomial model consisting of
independent variables significantly associated with com-
pletion of LTBI therapy at p< 0.10 by univariate analysis
plus any significant confounders. Significant confound-
ing was defined as a change in the risk ratio for a second
variable of interest of >10% when the confounder was
included (vs. not included) in the model.
Geospatial analysis
Residences of study participants were geocoded and
mapped using ArcMap 9.3 GIS software. The point
density analyst tool was used to calculate distances be-
tween each residence address and the Wake County
Health Department. Mean distance from the health de-
partment was compared between those who initiated
and completed therapy and those who did not, using the
student’s t-test. Residence zip codes were linked to per-
centage of area residents living below the poverty line in
each zip code, based on Census 2000 data. Zip codes
with less than 5% of the population living below the pov-
erty line were categorized as “Low poverty,” those with
5-10% below the poverty line “Moderate poverty” and
those with greater than 10% below the poverty line
“High poverty.” Univariate relationships between these




The 496 participants were predominantly foreign-born
(65%) and racial/ethnic minorities (87%), with mean age
39.1+ 12.3 years (Table 2). Of the 496, 130 (26%) persons
initiated LTBI therapy and 70 (54% of those initiating)
completed therapy. Of those who were foreign-born, the
most frequent regions of origin were Africa (19%) and
Latin America (20%). 61% of persons included in thestudy were referred after a tuberculin skin test (TST) was
performed as part of employment screening, and 19%
received a TST as part of a contact investigation. The
overall cohort included a number of former or current
smokers (32%), drug users (9%), and persons with history
of incarceration (14%) or homelessness (11%).LTBI treatment initiation
In the univariate analysis, factors significantly associated
with treatment initiation (P< 0.10) included older age,
African birthplace, close contact with an infectious TB
case, non-employment reason for TST, end-stage renal
disease (ESRD), immunosuppressed status, HIV infec-
tion, previous incarceration, residence in current home
for greater than one year, plans to remain at same home
greater than one year, lower educational level, having a
regular physician, and fear of getting sick with tubercu-
losis (Tables 1 and 2). In multivariable analysis, close
contact with a TB case, non-employment reason for
screening, lower educational level, having a regular phys-
ician, fear of getting sick with TB, and prior incarcer-
ation were independently associated with treatment
initiation (Table 3). Since there were few (n< 20) per-
sons with specific medical risk factors (ESRD, immuno-
suppressed status, HIV), medical and social risk were
collapsed into three risk strata as described in the Meth-
ods section. More persons at “high risk” of progressing
to and/or transmitting active TB initiated LTBI therapy
(54/120, 45%) than those at “moderate risk” (24/69, 35%)
or “low risk” (52/307, 17%)(P< 0.01).LTBI treatment completion
Among those initiating treatment, factors associated
with treatment completion (P< 0.10) included African
or Asian birthplace, absence of tobacco history, prior in-
carceration, and plan to tell friends/family about positive
TST. In multivariable analysis, planning to tell friends/
family about positive TST was independently and signifi-
cantly associated with treatment completion (RR 2.0,
95% CI 1.0-3.9). The proportion of persons at high risk
of progressing to and/or transmitting active TB complet-
ing therapy was not significantly different from those at
moderate or low risk (p = 0.6).
Of those persons initiating therapy, 31 were prescribed
rifampin, with a 61% completion rate, and 99 persons
were prescribed INH, with a 52% nine-month comple-
tion rate (p = 0.3). At least six months of INH was com-
pleted by 62/99 (63%) persons. Seven persons were
switched from isoniazid to rifampin, and four of these
completed a full course of rifampin. One person was
switched from rifampin to isoniazid and that individual
completed a full course of isoniazid. Compliance with
both therapies declined over time (Figure 1).
Table 2 Demographics, Risk Factors and Behaviors among Study Population with Latent TB Infection
Variable N (%) or N (%) or P value N (%) or P value€
Mean (SD) Mean (SD) Mean (SD)
Total Population Who Initiated Therapy Who Completed Therapy
Race/ethnicity
Asian/Pacific
Islander 70 (14) 16 (23) 0.2 12 (75) 0.1
Non-Hispanic White 64 (13) 10 (16) 3 (30)
Non-Hispanic Black 254 (51) 67 (26) 39 (58)
Hispanic 92 (19) 28 (30) 12 (43)
Other/unknown 16 (3)
Gender
Male 236 (48) 67 (28) 0.3 39 (58) 0.3
Female 260 (52) 63 (24) 31 (49)
Mean age 39.1 (12.3) 42.1 (38.0) <0.01 42.8 (41.2) 0.5
US-born 169 (34) 57 (34) 0.01 26 (46) 0.07
Region of birth
Developed world (US, Canada,
Western Europe, Japan)* 175 (35) 57 (33) 0.01 26 (46) 0.03
Africa 94 (19) 17 (18) 0.23 13 (77) 0.04
Asia 65 (13) 16 (25) 0.07 12 (75) 1
Eastern Europe 13 (3) 1 (8) 0.87 0 (0) 0.8
Latin America 98 (20) 31 (32) 0.06 15 (48) 1
Middle East 19 (4) 2 (11) 0.12 1 (50) 1
Other/unknown 32 (7) 6 (19) 3 (50)
Reason for skin testing
Employment screening * 304 (61) 50 (17) <0.01 25 (50) 0.3
Contact to TB case 94 (19) 50 (53) <0.01 30 (60) 1
Non-employment reason 98 (20) 30 (31) 15 (50)
Mean distance from health department (miles) 7.9 (9.5) 0.4 8.0 (7.7) 0.9
Neighborhood poverty level
Low poverty 74 (20) 16 (22) 0.6 13 (81) 0.08
Moderate poverty 155 (41) 39 (25) 19 (49)
High poverty 149 (39) 42 (28) 22 (42)
Alcohol use
None 316 (64) 82 (26) 0.7 41 (50) 0.3
<1 drink/day 106 (21) 31 (29) 22 (71)
1-2 drinks/day 23 (5) 5 (22) 2 (40)
3+ drinks/day 23 (5) 4 (17) 2 (50)
Binge 15 (3) 5 (33) 2 (40)
Smoking
None 322 (65) 84 (26) 0.7 51 (61) 0.04
Former 59 (12) 18 (31) 10 (56)
Current 100 (20) 25 (25) 8 (32)
Crack cocaine use 34 (7) 12 (35) 0.2 4 (33) 0.2
Diabetes 28 (6) 11 (39) 0.1 7 (64) 0.5
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Table 2 Demographics, Risk Factors and Behaviors among Study Population with Latent TB Infection (Continued)
ESRD 3 (1) 3 (100) 0.02 1 (33) 0.6
Gastrectomy 6 (1) 3 (50) 0.2 3 (100) 0.3
Heroin use 8 (2) 2 (25) 1 0 (0) 0.2
Homeless 53 (11) 18 (34) 0.2 8 (44) 0.4
IV drug use 12 (2) 3 (25) 1 0 (0) 0.1
Immunosuppressed 7 (1) 5 (71) 0.02 1 (20) 0.2
Prior incarceration 67 (14) 24 (36) 0.06 9 (38) 0.07
Long term care facility 71 (14) 12 (17) 0.05 8 (67) 0.4
Evidence of old TB on CXR 11 (2) 1 (9) 0.3 0 (0) 0.4
History of organ or bone marrow transplantation 1 (0) 0 (0) 1 0 (0) 1
Underweight 9 (2) 2 (22) 1 1 (50) 1
HIV 6 (1) 4 (67) 0.03 0 (0) 0.05
*Used as reference category for 2-group comparisons to calculate p-value.
€ P-values represent differences in proportions initiating/completing treatment among responses (not including missing responses).
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In geographic analysis, 391 residential addresses were
mapped with ArcGIS software. Of the 130 who initiated
therapy, 99 participants had addresses that could be
mapped to a physical location in North Carolina. Dis-
tance from the health department was not significantly
different between addresses of persons who initiated
LTBI therapy and those who did not initiate therapy
(p = 0.4). Similarly, treatment completion was not signifi-
cantly associated with distance from the health depart-
ment (p = 0.9). Of all participants, 378 participants had
zip codes with poverty data available from the 2000 U.S.
census. Treatment initiation did not vary significantly by
whether a participant lived in a high, moderate, or low-
poverty level area (p = 0.6). Of those who initiated ther-
apy, there was a trend toward greater completion of
therapy by persons living in a low-poverty area (81% of
those initiating completed therapy), compared to those
living in a moderate (49% completed) or high poverty
area (42%), at p = 0.08.
Discussion
Previous authors have evaluated demographic and
medication-based predictors of LTBI treatment non-Table 3 Multivariable model (log binomial) predicting initiati
Category Factor
Treatment Initiation Close contact to a TB case
Non-employment reason for sc
Lower educational level
Having a regular physician
Fear of getting sick with TB wit
Prior incarceration
Treatment Completion Plan to tell friends or family abocompletion, but few, if any, have prospectively evaluated a
combination of pre-treatment attitudes, behaviors, geo-
graphic, and medical risk factors as they relate to both ini-
tiating and completing therapy.
Furthermore, while several studies have evaluated medi-
cation completion in a cohort of patients already initiated
on therapy [2,4,14,16], one of the most interesting obser-
vations in our study was the fact that initiating, rather
than completing, treatment was the major challenge in
the LTBI program. While about half (55%) of persons ini-
tiating therapy completed, only about a quarter (26%)
even initiated therapy by picking up the first month’s sup-
ply of pills. The initiation rate in our study is notably less
than the 91% LTBI therapy initiation rate seen in a cohort
of patients presenting to TB clinic at Boston Medical Cen-
ter [12], 58% initiation rate in a population of health care
workers in Toronto [19], and 67% initiation rate in a co-
hort of HIV-infected patients in Spain [20]. Differences in
initiation rates between our study and others may be at-
tributable to different clinic populations, healthcare sys-
tems, and the fact that our study, as a program evaluation,
included all persons prescribed LTBI treatment without
selection bias. For comparison, among all contact investi-






hout medicine 1.7 1.2-2.6
1.7 1.1-2.8
ut LTBI diagnosis 2.0 1.0-3.9
Figure 1 Adherence to latent tuberculosis infection by therapy, Wake County 2008–2009. In this study, of persons initiating therapy, 31
were prescribed rifampin, with a 61% completion rate, and 99 persons were prescribed INH, with a 52% nine-month completion rate (p = 0.3). At
least six months of INH was completed by 62/99 (63%) persons. Compliance with both therapies declined over time.
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contacts in North Carolina in 2009, 67% of those infected
started treatment (Kitty Herrin, PhD, personal communi-
cation), consistent with our data that close contacts to an
infectious TB case are 2.5 times as likely to start therapy
than non-contacts.
This study also demonstrated that those with prior incar-
ceration were also more likely to initiate therapy, likely be-
cause LTBI treatment was started in a jail or prison setting,
although this data was not specifically documented. Rou-
tine access to medical care with a regular physician also
increased likelihood of therapy initiation, suggesting that
continuity of primary care can improve TB control efforts.
Contrary to our hypothesis, persons we classified as
higher risk of progression to active TB were more likely to
initiate LTBI treatment than persons at lower risk. Unfor-
tunately, even in these high-risk groups, though, a rela-
tively low proportion of participants with LTBI initiated
treatment. The likelihood that LTBI treatment would be
completed once initiated had no relationship to risk
group. Completion was associated with the plan to dis-
close LTBI diagnosis with friends or family, suggesting
that invitation of support members to clinic visits or to
otherwise engage in a patient’s care may improve comple-
tion rates. Other novel and cost-efficient interventions
need to be studied to improve both initiation and comple-
tion of LTBI treatment. In a California study of LTBI treat-
ment in drug users, therapy completion rate was 53%
when active outreach was used with a financial incentive
of five dollars per visit, compared to 4% when active out-
reach was used alone (p< 0.0001) [22]. A nonmonetary
incentive such as a nutritional supplement has also been
associated with increased LTBI therapy completion [23].
Directly observed therapy has had less success in increas-
ing treatment completion [24], and educational interven-
tions have had variable impact on adherence.The impact of a case of active TB may differ based
upon where the case occurs. A case in a relatively high-
poverty area, further from the health department, may
take longer to detect because of financial and logistical
barriers to seeking TB-related healthcare [15,17]. While
distance from the health department and the economic
status of the patient’s neighborhood were not related to
the probability of initiating LTBI treatment, of those
who initiated therapy, there was a trend toward greater
completion of therapy by persons living in low-poverty
areas than persons living in higher poverty areas. The
higher completion in lower-poverty areas may be due to
ease of access to healthcare, local social factors, or other
unmeasured factors. Also, while distance to the health
department from a participant’s residential address was
not significantly related to the probability of initiating or
completing LTBI treatment, the distance measures used
in our study are only rough approximations of the time
required to get to the health department.
In terms of study limitations, results may be less
generalizable given this was a single-clinic cohort. Further-
more, employment screening, a less targeted approach,
was a frequent reason for TST placement and medication
prescription in this clinic; this type of screening was dis-
continued in part as a result of this analysis. Finally, the
small number of participants with key risk factors for LTBI
(HIV, immunosuppressed conditions, etc.) and overall
small numbers in the completion group limited the power
of multivariable analysis.
Conclusion
Initiation of treatment was the major challenge in our
program. Investment in non-employment based screen-
ing, social support, and in treatment completion by per-
sons at high risk of developing TB, may improve control
efforts in low-incidence settings.
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